Semin Liver Dis 2010; 30: 052-060DOI: 10.1055/s-0030-1247132ABSTRACTThe endpoint in cancer research is overall survival. Nonetheless, other potential surrogate endpoints, such as response rate and time to progression, are currently used. Measurement of response rate in hepatocellular carcinoma (HCC) has become a controversial issue. The World Health Organization (WHO) criteria underestimate the actual response rate; thus, they were amended in 2000 by a panel of experts convened by the European Association for the Study of the Liver (EASL) to take into account treatment-induced tumor necrosis. Applying these guidelines, there was an association between response rate and outcome prediction. More recently, the Response Evaluation Criteria in Solid Tumors (RECIST) guideline was proposed as a m…
Further information:
Related posts:
- Pathology of Early Hepatocellular Carcinoma: Conventional and Molecular Diagnosis
- Hepatocellular Carcinoma and Hepatic Adenocarcinosarcoma in a Patient with Hepatitis B Virus-Related Cirrhosis
- Identification of Novel Oncogenes and Tumor Suppressors in Hepatocellular Carcinoma
- Hepatocellular Carcinoma: Epidemiology, Surveillance, and Diagnosis
- Institutional guidelines and ongoing studies in management of liver tumours: The experience of the European Institute of Oncology
Posted in